FIG 2.
Kaplan-Meier survival curves depicting OS and GFFS by underlying diagnosis (A), donor type (smallest subgroup of mismatched unrelated donor and cord excluded, n = 5) (B), conditioning intensity (smallest subgroup of nonmyeloablative/immunosuppression only conditioning excluded, n = 1) (C), or serotherapy choice (of note, follow up is shorter for smaller subgroups of horse antithymocyte globulin [ATG] and intermediate timing alemtuzumab) (D). NS, Not significant.